<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=7559&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="412804" class="table-">
                
                <td>June 9, 2022, 4 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            None
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Serological response to vaccination as measured by VNA titers, 14 Days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported.

Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Antibody titer as measured by VNA titers, 14 days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported.

Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ]
Serological response to vaccination as measured by VNA titers, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported.

Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ]
Antibody titer as measured by VNA titers, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported.

Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported.

Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Antibody titers as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported

Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ]
Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported.

Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ]
Antibody titers as measured by VNA titers against the leading variant of high consequence or concern, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported.

Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Serological response to vaccination as measured by VNA titers, 14 days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with BNT162b2 will be reported.

Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Antibody titer as measured by VNA titers, 14 days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with BNT162b2 will be reported.

Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ]
Serological response to vaccination as measured by VNA titers against the original strain, in Pfizer BNT162b2 external samples will be reported.

Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ]
Antibody titers as measured by VNA titers against the original strain, in Pfizer BNT162b2 external Samples will be reported.

Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with BNT162b2 will be reported.

Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ]
Antibody titers as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with BNT162b2 will be reported.

Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ]
Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern in Pfizer BNT162b2 external samples will be reported

Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ]
Antibody titers as measured by VNA titers against the leading variant of high consequence or concern in Pfizer BNT162b2 external samples will be reported
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="166204" class="table-">
                
                <td>Nov. 16, 2021, 6:30 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 9, 2022, 4 p.m.	usa	None	Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Serological response to vaccination as measured by VNA titers, 14 Days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported. Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Antibody titer as measured by VNA titers, 14 days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported. Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ] Serological response to vaccination as measured by VNA titers, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported. Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ] Antibody titer as measured by VNA titers, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported. Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported. Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Antibody titers as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with Ad26.COV2.S (dose level 1) will be reported Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ] Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported. Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S [ Time Frame: 28 days after primary vaccination (Day 29) ] Antibody titers as measured by VNA titers against the leading variant of high consequence or concern, 28 days after primary vaccination with Ad26.COV2.S (dose level 1) will be reported. Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Serological response to vaccination as measured by VNA titers, 14 days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with BNT162b2 will be reported. Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Antibody titer as measured by VNA titers, 14 days after Ad26.COV2.S (dose levels 1, 2 and 3) booster vaccination after completing primary vaccination with BNT162b2 will be reported. Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ] Serological response to vaccination as measured by VNA titers against the original strain, in Pfizer BNT162b2 external samples will be reported. Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ] Antibody titers as measured by VNA titers against the original strain, in Pfizer BNT162b2 external Samples will be reported. Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with BNT162b2 will be reported. Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2 [ Time Frame: 14 days after booster vaccination after completing primary vaccination (Day 15) ] Antibody titers as measured by VNA titers against the leading variant of high consequence or concern, 14 days after Ad26.COV2.S booster vaccination after completing primary vaccination with BNT162b2 will be reported. Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ] Serological response to vaccination as measured by VNA titers against the leading variant of high consequence or concern in Pfizer BNT162b2 external samples will be reported Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples [ Time Frame: Up to 2 months after completing primary vaccination with Pfizer BNT162b2 ] Antibody titers as measured by VNA titers against the leading variant of high consequence or concern in Pfizer BNT162b2 external samples will be reported
Nov. 16, 2021, 6:30 p.m.	usa	Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S	Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S